Moreover, subgroup analysis of the outcome for the 13 patients with previous leukopenia before therapy indicated that the common dose of AZA may be safe and effective for patients with wild-type NUDT15 homozygotes. The gene discussed is NUDT15; the disease is Decreased total leukocyte count.